Thailand to Offer Free Infant Pneumonia Vaccine Under Universal Health Coverage

The Thailand National Health Security Office (NHSO) has advanced the inclusion of the pneumococcal conjugate vaccine (PCV) into the universal coverage benefit package, a move that will protect thousands of Thai infants from life-threatening infections and reduce out-of-pocket costs for families.

Key Takeaways

• Regulatory milestone achieved – legal affairs subcommittee approved the PCV draft regulation.

• Budget squeeze – ฿225 million can only cover about 100,000 children at current per-dose rates.

• Price talks underway – aiming for ฿70–100 per dose, matching UNICEF/Gavi bulk-buy benchmarks.

• Nationwide plan – three-dose schedule at 2, 4 and 12 months, targeting full rollout by late 2026.

Behind the Green Light

Last week, a subcommittee on legal affairs under the National Health Security Board gave its nod to a draft announcement listing PCV as a core benefit under Thailand’s บัตรทอง scheme.The next step is for Public Health Minister Pattana Promphat, who chairs the board, to sign the regulation so it can be published in the Royal Gazette and become law.

Negotiating for Value

With roughly 400,000 births each year, a full three-dose course currently quoted at ฿200 per shot would demand upward of ฿300–400 million annually—well beyond the allocated ฿225 million for disease prevention. To bridge that gap, the NHSO has instructed procurement teams to push vaccine makers for prices in line with international procurement channels like UNICEF and Gavi, the Vaccine Alliance, where PCV often trades for US$2.90 (≈฿100) or lower.

Balancing Pilot and Scale

Initially, the NHSO planned a one-year pilot in selected high-burden areas—health regions 6, 8 and 9—to refine cold-chain logistics and community outreach. Experience from a 2021–22 trial in Maha Sarakham Province (first-dose coverage 44%, third-dose 10%) will inform this phase. However, thanks to strong advocacy from pediatricians and evidence of cost-effectiveness, the board is eyeing a nationwide launch in 2026, with high-risk provinces receiving the first shipments if global supply is limited.

Expert Backing and Economic Rationale

Thailand’s pediatric societies, backed by WHO guidance, have long argued that PCV is an essential childhood vaccine. Studies by HITAP and the National Vaccine Institute confirm that even without herd-immunity effects, the program pays for itself within 10 years through reduced hospital admissions and long-term disability costs. Physicians warn that, without PCV under บัตรทอง, rural and low-income families face a two-tier system where urban parents can pay ฿7,000–8,000 privately while others remain unprotected.

What This Means for Residents

• Automatic scheduling: Newborns will see PCV slots appear in the Mor Prom app when they turn 2 months old.

• Zero co-payment: Public hospitals and network private clinics will administer all three doses at no charge under บัตรทอง.

• Foreigners on UCS: Expats and migrant families enrolled in universal coverage receive identical entitlements; privately insured should confirm with providers.

• Community outreach: Village health volunteers (อสม.) will track infants in hard-to-reach and migrant communities to close coverage gaps.

Next Steps and Timeline

After Minister Pattana’s signature, the regulation will be gazetted—expected in Q2 2026—triggering vaccine orders and distribution plans. Provincial health offices will monitor uptake through the MOPH Immun Link system, while procurement teams finalize dose pricing by mid-year. If negotiations secure ฿70–100 per dose, the NHSO’s budget could stretch to cover over 200,000 children, accelerating full national protection against pneumococcal disease.